Form 4: TECOGEN Director Earl Lewis Granted 25,000 Stock Options Under 10b5-1 Plan

TECOGEN Inc. Director Earl R. Lewis was granted 25,000 stock options with an exercise price of $8.35, vesting annually over four years, as part of a pre-arranged Rule 10b5-1 plan.

Summary

• Earl R. Lewis, a Director of TECOGEN Inc. (TGEN), was granted 25,000 stock options.
• The transaction date for the option grant is July 24, 2025.
• The exercise price for these options is $8.35 per share.
• The options begin vesting on July 24, 2026, at a rate of 25% per year.
• The options have an expiration date of July 24, 2035.
• Following this transaction, Mr. Lewis beneficially owns 91,250 derivative securities (stock options).
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a director, which is a positive for aligning interests but does not represent a significant new development for the company's overall financial health or strategic direction.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of TECOGEN Inc.
• The use of a Rule 10b5-1 plan demonstrates a pre-planned and transparent approach to insider equity transactions.

Future Outlook

The stock options granted to Director Earl R. Lewis are set to vest over the next four years, indicating a continued long-term incentive and commitment to the company's future performance.

Industry Context

The grant of stock options to a director is a common practice in corporate compensation, designed to incentivize long-term performance and align the interests of management and board members with those of shareholders.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including the energy and technology sectors where TECOGEN operates.
• The vesting schedule of 25% per year over four years is a typical structure for equity grants, promoting retention and long-term commitment.

Related Party Transactions

• The grant of 25,000 stock options to Earl R. Lewis, a Director of TECOGEN Inc., constitutes a related party transaction as it involves an equity award from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, but also represents potential future dilution upon exercise of the options.
• Director (Earl R. Lewis): Receives a significant equity incentive tied to the company's future stock performance.

Next Steps

• The granted stock options will begin vesting on July 24, 2026, and continue annually thereafter.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice and aligns the director's interests with long-term shareholder value. It does not provide new material information that would significantly alter an investment thesis for TECOGEN Inc. or warrant a change in stock recommendation.

Keywords

TECOGEN, TGEN, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Rule 10b5-1